Ceryvyn Therapeutics Ltd Financials

Ceryvyn Therapeutics Ltd (OPTEY) reported $25K in total revenue for fiscal year 2025. This represents a -80.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Ceryvyn Therapeutics Ltd (OPTEY) revenue declined by 80% year-over-year, from $125K to $25K in fiscal year 2025.

No, Ceryvyn Therapeutics Ltd (OPTEY) reported a net income of -$162.8M in fiscal year 2025, with a net profit margin of -651164.0%.

Ceryvyn Therapeutics Ltd (OPTEY) had a net profit margin of -651164.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Ceryvyn Therapeutics Ltd (OPTEY) generated -$158.7M in free cash flow during fiscal year 2025. This represents a 1.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Ceryvyn Therapeutics Ltd (OPTEY) generated -$158.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Ceryvyn Therapeutics Ltd (OPTEY) had $56.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Ceryvyn Therapeutics Ltd (OPTEY) invested $13K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Ceryvyn Therapeutics Ltd (OPTEY) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Ceryvyn Therapeutics Ltd (OPTEY) had a debt-to-equity ratio of -1.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Ceryvyn Therapeutics Ltd (OPTEY) had a return on assets of -286.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Ceryvyn Therapeutics Ltd (OPTEY) had $48.4M in cash against an annual operating cash burn of $158.6M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Ceryvyn Therapeutics Ltd (OPTEY) has negative shareholder equity of -$201.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Ceryvyn Therapeutics Ltd (OPTEY) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Ceryvyn Therapeutics Ltd (OPTEY) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.